Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

8448 results about "Methacrylate" patented technology

Methacrylate refers to derivatives of methacrylic acid. These derivatives include the parent acid (CH₂C(CH₃)CO₂H), salts (e.g., CH₂C(CH₃)CO⁻₂Na⁺), esters (e.g. CH₂C(CH₃)CO₂CH₃, or methyl methacrylate) and the polymers of these species.

Sulfonated block copolymers, method for making same, and various uses for such block copolymers

The present invention is a, solid block copolymer comprising at least two polymer end blocks A and at least one polymer interior block B wherein each A block is a polymer block resistant to sulfonation and each B block is a polymer block susceptible to sulfonation, and wherein said A and B blocks do not contain any significant levels of olefinic unsaturation. Preferably, each A block comprising one or more segments selected from polymerized (i) para-substituted styrene monomers, (ii) ethylene, (iii) alpha olefins of 3 to 18 carbon atoms; (iv) hydrogenated 1,3-cyclodiene monomers, (v) hydrogenated monomers of conjugated dienes having a vinyl content less than 35 mol percent prior to hydrogenation, (vi) acrylic esters, (vii) methacrylic esters, and (viii) mixtures thereof; and each B block comprising segments of one or more polymerized vinyl aromatic monomers selected from (i) unsubstituted styrene monomers, (ii) ortho-substituted styrene monomers, (iii) meta-substituted styrene monomers, (iv) alpha-methylstyrene, (v) 1,1-diphenylethylene, (vi) 1,2-diphenylethylene and (vii) mixtures thereof. Also claimed are processes for making such block copolymers, and the various end uses and applications for such block copolymers.
Owner:KRATON POLYMERS US LLC

Drug delivery compositions and medical devices containing block copolymer

A composition for delivery of a therapeutic agent is provided. The composition comprises: (a) a biocompatible block copolymer comprising one or more elastomeric blocks and one or more thermoplastic blocks and (b) a therapeutic agent, wherein the block copolymer is loaded with the therapeutic agent. The block copolymer is preferably of the formula X—(AB)n, where A is an elastomeric block, B is a thermoplastic block, n is a positive whole number and X is a seed molecule. The elastomeric blocks are preferably polyolefin blocks, and the thermoplastic blocks are preferably selected from vinyl aromatic blocks and methacrylate blocks. According to another aspect of the invention, a medical device is provided, at least a portion of which is insertable or implantable into the body of a patient. The medical device comprises (a) the above biocompatible block copolymer and (b) a therapeutic agent, wherein the block copolymer is loaded with the therapeutic agent. According to another aspect of the present invention, a method of treatment is provided in which the above device is implanted or inserted into a patient, resulting in the release of therapeutic agent in the patient over an extended period. According to yet another aspect of the invention, a coated medical device is provided which comprises: (a) an intravascular or intervascular medical device and (b) a coating over at least a portion of the intravascular or intervascular a medical device, wherein the coating comprises the above biocompatible block copolymer.
Owner:SCI MED LIFE SYST

Injection molding method for neutral and acidic-group containing (meth)acrylate copolymers

The invention relates to a process for producing mouldings by injection moulding, the steps in the process being A) Melting a mixture made from a) a (meth)acrylate copolymer composed of from 40 to 100% by weight of free-radical-polymerized C1-C4-alkyl esters of acrylic or methacrylic acid and from 0 to 60% by weight of (meth)acrylate monomers having an anionic group in the alkyl radical, where the copolymer comprises b) from 0.1 to 3% by weight of a release agent, and, where appropriate, the mixture may comprise c) from 0 to 50% by weight of a drier, d) from 0 to 30% by weight of a plasticizer, e) from 0 to 100% by weight of additives or auxiliaries, f) from 0 to 100% by weight of an active pharmaceutical ingredient, g) from 0 to 20% by weight of another polymer or copolymer, where the amounts given for components b) to g) are based on the (meth)acrylate copolymer a) and the mixture prior to melting has a content of more than 0.5% by weight of low-boiling constituents with vapour pressure of at least 1.9 bar at 120° C., B) Devolatilizing the mixture in the thermoplastic state at temperatures of at least 120° C., thereby lowering to not more than 0.5% by weight the content of the low-boiling constituents with vapour pressure of at least 1.9 bar at 120° C., C) Injecting the molten and devolatilized mixture into the mould cavity of an injection mould, the temperature of the mould cavity being below the glass transition temperature of the (meth)acrylate copolymer by at least 10° C., cooling the molten mixture, and removing the resultant moulding from the mould.
Owner:PFIZER INC +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products